These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 28285684)

  • 1. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ
    Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
    Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA
    J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
    Lin YT; Yu CJ; Yang JC; Shih JY
    Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Ou SH; Milliken JC; Azada MC; Miller VA; Ali SM; Klempner SJ
    Lung Cancer; 2016 Jan; 91():70-2. PubMed ID: 26464158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
    Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.
    Zhu VW; Cui JJ; Fernandez-Rocha M; Schrock AB; Ali SM; Ou SI
    Lung Cancer; 2017 Aug; 110():32-34. PubMed ID: 28676215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
    Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
    Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
    Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
    Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
    Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
    Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
    Shaw AT; Friboulet L; Leshchiner I; Gainor JF; Bergqvist S; Brooun A; Burke BJ; Deng YL; Liu W; Dardaei L; Frias RL; Schultz KR; Logan J; James LP; Smeal T; Timofeevski S; Katayama R; Iafrate AJ; Le L; McTigue M; Getz G; Johnson TW; Engelman JA
    N Engl J Med; 2016 Jan; 374(1):54-61. PubMed ID: 26698910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
    Makimoto G; Ohashi K; Tomida S; Nishii K; Matsubara T; Kayatani H; Higo H; Ninomiya K; Sato A; Watanabe H; Kano H; Ninomiya T; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Toyooka S; Takata M; Maeda Y; Kiura K
    J Thorac Oncol; 2019 Nov; 14(11):2009-2018. PubMed ID: 31374369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
    Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
    Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
    Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
    Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.